Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

InSilico Medicine, CCARL collaborate to improve personalized medicine projects in multiple sclerosis

InSilico Medicine, the company focused on drug discovery for cancer and age-related diseases, announced its investment in a research collaboration with Canada Cancer and Aging Research Laboratories, Inc. The companies will collaborate on improving decision making in clinical oncology and discovery, and personalized medicine projects in multiple sclerosis (MS).

27 Oct 2014

Crown Bioscience announces U.S. expansion with new translational oncology center

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced the opening of the Crown Bioscience US Research Center to be located at the David H. Murdock Research Institute (DHMRI), in Kannapolis, N.C. The new center, which will open in the 3rd quarter of 2014, represents significant U.S. market expansion for Crown.

21 Oct 2014

Scientists identify potent inhibitors to combat common obesity gene

Individuals who are genetically predisposed to obesity may soon have a therapeutic solution to combat their condition. A research team led by scientists from the National University of Singapore (NUS) has identified several potent inhibitors that selectively target FTO, the common fat mass and obesity-associated gene.

21 Oct 2014

Identifying infections rapidly: an interview with Dr. David J. Ecker

Current methods for diagnosing infectious diseases are based on the 150-year-old culture method, where physicians collect a sample of a patient’s tissue, such as blood, mucus or urine, and transfer it onto media bottle to allow the pathogens to grow.

From Abbott Diagnostics 20 Oct 2014

Treeway, LACDR join forces to optimize clinical trial designs, data-analysis for ALS

Treeway and LACDR at the University of Leiden join forces and form a collaboration focused on the optimization of clinical trial designs and data-analysis for ALS (Amyotrophic Lateral Sclerosis) through the use of population disease progression models.

16 Oct 2014

Leading UK supplier uses INTEGRA’s VIAFLO II, VIAFLO ASSIST to improve assay consistency

A leading UK supplier of early-stage drug discovery and development process services has improved the consistency and efficiency of its assays using VIAFLO II pipettes and a VIAFLO ASSIST from INTEGRA. By mounting a VIAFLO II electronic pipette on the VIAFLO ASSIST, the pipette’s protocols can be carried out fully automatically.

From INTEGRA Biosciences 15 Oct 2014

New culture system confirms amyloid theory, can revolutionize drug discovery for Alzheimer's disease

An innovative laboratory culture system has succeeded, for the first time, in reproducing the full course of events underlying the development of Alzheimer's disease.

13 Oct 2014

Pharmaceutical industry withdraws from the antibiotic space

The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive.

13 Oct 2014

HemoShear completes first-phase development of novel cancer drug discovery platform

HemoShear today announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations.

9 Oct 2014

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

9 Oct 2014

Porvair Sciences appoints SPEware Corporation as its exclusive partner

Porvair Sciences, a world leader in applications optimised microplates and microplate equipment has appointed SPEware Corporation (Baldwin Park, CA) as its exclusive partner for supporting and servicing its UltraVap, MiniVap and UltraVap Mistral microplate sample concentration systems.

From Chromatrap® - Porvair Sciences Ltd 9 Oct 2014

Researchers use computer based predictions to combat AIDS

The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.

8 Oct 2014

Case Western Reserve researcher lands Director's New Innovator Awards from NIH

For the second consecutive year, a Case Western Reserve University School of Medicine researcher has landed one of the year's much-coveted Director's New Innovator Awards from the National Institutes of Health. Principal investigator Rong Xu, PhD, assistant professor of medical informatics, will receive $2,377,000 for five years, starting immediately, to initiate computational analysis of thousands of drugs and their effects.

8 Oct 2014

New drug discovery tool against Ebola virus

University of Utah biochemists have reported a new drug discovery tool against the Ebola virus. According to a study published in this week's online edition of Protein Science, they have produced a molecule, known as a peptide mimic, that displays a functionally critical region of the virus that is universally conserved in all known species of Ebola.

8 Oct 2014

2014 Norman R. Alpert Award winner announced

Dr. Chris Berger, CMB Interim Director and Director of Graduate Education for the College of Medicine, announced the winner of the 2014 Norman R. Alpert Award at the annual Graduate Research Day for the CMB Program event held October 2, 2014. Jacqueline Leung, a graduate student in the Cellular, Molecular and Biosciences (CMB) Program at the University of Vermont won for her publication, “Identification of T. gondii Myosin Light Chain-1 as a Direct Target of TachypleginA-2, a Small-Molecule Inhibitor of Parasite Motility and Invasion.”1

6 Oct 2014

NJHF awards grant to help launch drug discovery facility at Rutgers University

In its continuing effort to advance the biomedical sciences, New Jersey Health Foundation has awarded a pivotal $35,000 grant to the Office of Translational Sciences at Rutgers, The State University of New Jersey, to help launch a Fragment Based Drug Discovery (FBDD) core facility.

29 Sep 2014

Pitt researchers awarded new $5.8 million NIH grant to develop microfluidic 3D liver model system

With a new $5.8 million, three-year award from the National Institutes of Health, researchers at the University of Pittsburgh School of Medicine will further develop a state-of-the-art, microfluidic 3D model system that mimics structure and function of the liver to better predict organ physiology, assess drug toxicity and build disease models.

25 Sep 2014

TSRI scientists awarded DARPA grant to build artificial immune system

Scientists from both campuses of The Scripps Research Institute have been awarded a total of $7.9 million from the Defense Advanced Research Projects Agency of the U.S. Department of Defense.

25 Sep 2014

Axio Research announces launch of Statistical Genetics and Genomics services

Axio Research announced today the launch of Statistical Genetics and Genomics services in response to the biopharmaceutical industry's need for advanced statistical support in the analysis and interpretation of complex genomic data for drug discovery and development, drug repositioning, and companion diagnostics development.

24 Sep 2014

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs).

24 Sep 2014

Drug Discovery News and Research

Further Reading

InSilico Medicine, CCARL collaborate to improve personalized medicine projects in multiple sclerosis

Crown Bioscience announces U.S. expansion with new translational oncology center

Scientists identify potent inhibitors to combat common obesity gene

Identifying infections rapidly: an interview with Dr. David J. Ecker

Treeway, LACDR join forces to optimize clinical trial designs, data-analysis for ALS

Leading UK supplier uses INTEGRA’s VIAFLO II, VIAFLO ASSIST to improve assay consistency

New culture system confirms amyloid theory, can revolutionize drug discovery for Alzheimer's disease

Pharmaceutical industry withdraws from the antibiotic space

HemoShear completes first-phase development of novel cancer drug discovery platform

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Porvair Sciences appoints SPEware Corporation as its exclusive partner

Researchers use computer based predictions to combat AIDS

Case Western Reserve researcher lands Director's New Innovator Awards from NIH

New drug discovery tool against Ebola virus

2014 Norman R. Alpert Award winner announced

NJHF awards grant to help launch drug discovery facility at Rutgers University

Pitt researchers awarded new $5.8 million NIH grant to develop microfluidic 3D liver model system

TSRI scientists awarded DARPA grant to build artificial immune system

Axio Research announces launch of Statistical Genetics and Genomics services

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Drug Discovery - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News